The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

VRd alone. At a median follow-up of 59.7 months, the median PFS with the Sarclisa-VRd combination was not reached versus 54.3 months with VRd. On Saturday, the FDA approved Sanofi’s SA SNY ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...